TB-500 for Health & Longevity - Quick Reference Sheet

TB-500 for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A lab-made copy of the most active part of a natural human repair protein, promoted for injury healing and longevity. Animal data are strong, but human proof for the injected form is essentially absent; the best human evidence is an eye-drop of the full protein. Main hazards: unregulated product quality and a theoretical cancer concern. (Full Review)

Protocol

Loading Dose
4–8 mg / week
First 4–6 weeks, often split into two subcutaneous injections
Maintenance Dose
2–6 mg / month
Lower dose after the loading phase; typically a single less-frequent injection
Course & Cycling
Time-limited, injury-linked
Loading-then-maintenance-then-off cycle to limit cumulative exposure
Time to effect
Soft-Tissue Recovery
Several weeks
Repair effects accumulate over the 4–6 week loading phase; no validated human timeline

Benefits

Contraindications
  • Active or recent cancer (or high cancer risk)
  • Pregnancy or breastfeeding
  • Competitive athletes under anti-doping rules (banned since 2011)
  • Inability to source a sterile, tested product
Key Interactions
  • Anti-angiogenic cancer therapies (bevacizumab)
  • Systemic corticosteroids
  • NSAIDs (ibuprofen, naproxen)
  • Other repair peptides (BPC-157)
  • Growth-hormone-axis interventions (growth-hormone secretagogues)

Risk & Side Effects

  • High:
  • Medium: Unregulated product quality, contamination, and dosing errors
  • Low: Injection-site and transient systemic reactions
  • Speculative: Theoretical cancer promotion; unknown long-term and immunogenic effects; fibrosis and vascular remodeling in uncontrolled settings

Monitoring

Marker Target Why
Complete Blood Count (CBC) Within lab reference; no unexplained shifts Screen for infection and hematologic changes during injectable use
High-sensitivity CRP (hs-CRP) <1.0 mg/L Track systemic inflammation given the peptide's anti-inflammatory claim
Comprehensive Metabolic Panel (CMP) Within lab reference Baseline liver and kidney function for overall safety surveillance
PSA (males) / age-appropriate cancer screening Age-appropriate reference; no rising trend Surveillance for the theoretical pro-tumor concern
Fasting glucose / HbA1c Glucose 70–90 mg/dL; HbA1c <5.4% Baseline metabolic health, relevant to healing capacity

Cadence: Baseline, then approximately every 8–12 weeks during active use, then at least annually if use continues, with age-appropriate cancer screening kept current.

Qualitative Assessment

  • Reduction in pain and improvement in function/range of motion at the target injury site
  • Faster-than-expected return to training or activity
  • Absence of injection-site reactions, infection, or persistent systemic side effects
  • Subjective energy, recovery quality, and sleep remaining stable or improved
  • No new or concerning symptoms (unexplained lumps, weight loss, or persistent pain) that would warrant stopping and medical review